Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of menís and womenís health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate, LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing, is in Phase III clinical study. The companyís pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase II clinical study; and LPCN 1107, which is in Phase I clinical study for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.